SHANGHAI, PHILADELPHIA and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...
Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced the presentation of new preclinical data supporting ...
First-in-class Flare platform designed to address targeting and resistance mechanisms in solid tumors to expand curative potential of immunotherapies for cancer patients Platform based on convergence ...
PHILADELPHIA & SAN FRANCISCO, January 12, 2026--(BUSINESS WIRE)--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, ...
Arch Venture Partners-funded Dispatch Bio has officially launched with $216 million in its coffers and a mission to find a universal antigen to treat solid tumors. Dispatch, based in Philadelphia and ...
Welcome to the roundup of the latest from Philly's tech and entrepreneurship scene. Want this in your inbox? Subscribe for free. This week in Philly, mapping the $90 billion investment in Pennsylvania ...
PHILADELPHIA & SAN FRANCISCO & SHANGHAI, January 12, 2026--(BUSINESS WIRE)--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare ...
SEND is a novel synthetic cytokine receptor designed to enable simultaneous activation of multiple T cell signaling pathways to enhance T cell efficacy and durability SEND demonstrates strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results